Skip to main content
SpringerLink
Log in

A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To investigate the feasibility of intrapatient dose-escalation methodology for dose-ranging studies of conventional cytotoxics in combination.

Patients and methods

Case records were identified for patients with ovarian cancer treated first-line with either single-agent carboplatin or carboplatin and paclitaxel in combination and routinely subjected to a 10% dose escalation in carboplatin at each cycle, towards a target day-22 neutrophil count in the range 1.0–1.5×109/l and a platelet count in the range 75–110×109/l, defining adequate dose. 'Entry level' carboplatin doses were in the range AUC 5.1 to AUC 7.4; paclitaxel was given at 175 mg/m2 as a 3-h infusion throughout. All drugs were administered three-weekly.

Results

The distribution of carboplatin maximum tolerated doses (MTDs) indicated a wide interpatient variation, ranging from AUC 5.4 to AUC 9.8. The median MTD in those receiving carboplatin alone (AUC 6.9) was significantly lower than in those treated with carboplatin and paclitaxel (AUC 7.6) (P=0.01). Also, paclitaxel had both neutrophil- and platelet-protective effects.

Conclusions

The median MTD documented here using intrapatient dose escalation for carboplatin combined with paclitaxel is remarkably similar to that derived from conventional phase I studies. Furthermore, the striking range of carboplatin MTDs recorded in previously untreated patients may have implications for the wider development of management strategies based on the adequacy of treatment, as defined by the modest levels of dose-limiting toxicity encountered. The ready availability of an expanded set of MTD data by this methodology may also provide more compelling evidence about potential pharmacodynamic drug interactions than may be available from conventional phase I combination studies. These retrospective findings clearly justify further prospective evaluation of intrapatient dose-escalation methodology in dose-ranging studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

References

  1. Bergh J (2000) Where next with stem-cell-supported high-dose therapy for breast cancer? Lancet 355:944–945

  2. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, Kellokumpu-Lehtinen P, Bengtsson NO, Soderlund G, Anker G, Wist E, Ottosson S, Salminen E, Ljungman P, Holte H, Nilsson J, Blomqvist C, Wilking N (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356:1384–1391

    Article  CAS  PubMed  Google Scholar 

  3. Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH, Ozols RF (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 14:1895–1902

    CAS  PubMed  Google Scholar 

  4. Calvert AH (1994) Dose optimisation of carboplatin in adults. Anticancer Res 14:2273–2278

    CAS  PubMed  Google Scholar 

  5. Calvert AH (1997) A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel. Semin Oncol 24 [Suppl 2]:85–90

  6. Calvert A, Newell D, Gumbrell L, O'Reilly S, Burnell M, Boxall F, Siddick Z, Judson I, Gore M, Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 17:1748–1756

    Google Scholar 

  7. Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L, Gumbrell L, Thomas H, Chapman F, Proctor M, Simmons D, Oakey A, Lind M, Sinha D, Newell D (1995) Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22:91–98; discussion 99–100

    CAS  Google Scholar 

  8. Canal P, Chatelut E, Guichard S (1998) Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 56:1019–1038

    CAS  PubMed  Google Scholar 

  9. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    CAS  PubMed  Google Scholar 

  10. Crown J, Lind M, Gould A, Verrill M, Twelves C, Coleman R, Perren T, Belle SV, Wilson C, Lederman J, Barrett-Lee PJ, Heart D, Kennedy I, Simmons P, Mansi JL, Jones A, Cameron D, Poole C, Foster L, Leonard R (2002) High-dose chemotherapy (HDC) with autograft (PBP) support is not superior to cyclophosphamide (CPA), methotrexate and 5-FU (CMF) following doxorubicin (D) induction in patients (pts) with breast cancer (BC) and 4 or more involved axillary lymph nodes (4+LN): the Anglo-Celtic I study. Proc Am Soc Clin Oncol 21:166a

    Google Scholar 

  11. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338:499–505

    CAS  PubMed  Google Scholar 

  12. Gordon AN, Hancock KC, Matthews CM, Stringer CA, Boston J, Nemunaitis J (1999) A phase I/II dose escalation study of carboplatin in the treatment of newly diagnosed patients with advanced ovarian cancer receiving paclitaxel. Am J Clin Oncol 22:601–605

    Google Scholar 

  13. Gore M, Mainwaring P, A'Hern R, MacFarlane V, Slevin M, Harper P, Osborne R, Mansi J, Blake P, Wiltshaw E, Shepherd J (1998) Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group. J Clin Oncol 16:2426–2434

    CAS  PubMed  Google Scholar 

  14. Harper P (1997) ICON-2 and ICON-3 data in previously untreated ovarian cancer: results to date. Semin Oncol 24 [Suppl 15]:23–25

  15. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, Martino S, Ingle J, Cooper M, Canellos G, Borden E, Fleming G, Holland J, Graziano S, Carpenter J, Muss H, Norton L (1998) Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (pts) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:390a

    Google Scholar 

  16. Homesley HD, Hall DJ, Martin DA, Lewandowski GS, Vaccarello L, Nahhas WA, Suggs CL, Penley RG (2001) A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients. Gynecol Oncol 83:394–399

    Article  CAS  PubMed  Google Scholar 

  17. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E (1992) Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 10:520–528

    CAS  PubMed  Google Scholar 

  18. Kearns CM, Egorin MJ (1997) Considerations regarding the less-than-expected thrombocytopenia encountered with combination paclitaxel/carboplatin chemotherapy. Semin Oncol 24 [Suppl 2]:91–96

  19. Legedza ATR, Ibrahim JG (2000) Longitudinal design for phase I clinical trials using the continual reassessment method. Controlled Clin Trials 21:574–588

    Article  CAS  PubMed  Google Scholar 

  20. O'Grady J, Joubert P (eds) (1997) Handbook of phase I/II clinical drug trials. CRC Press, Boca Raton

  21. Ozols R, Greer B, Baergen R, Reed E (2002) Gynecologic Oncology Group, Statistical Report Protocol no. 158

  22. Pestalozzi B, Schwendener R, Sauter C (1992) Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3:445–449

    CAS  PubMed  Google Scholar 

  23. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C (1999) Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 80:1763–1766

    Google Scholar 

  24. Poole C, Jordan S, Higgins H, Archer V, Pemberton G (2001) A phase I intra and interpatient dose ranging trial of gemcitabine, carboplatin and paclitaxel (GCP) in combination in previously untreated patients with epithelial ovarian cancer, primary peritoneal malignancy, ovarian carcinosarcoma and fallopian tube carcinoma. Proc Am Soc Clin Oncol 20:848a

    Google Scholar 

  25. Rankin E, Mill L, Kaye S, Atkinson R, Cassidy L, Cordiner J, Cruickshank D, Davis J, Duncan I, Fullerton W, Habeshaw T, Kennedy J, Kennedy R, Kitchener H, MacLean A, Paul J, Reed N, Sarker T, Soukoup M, Swapp G, Symonds P (1992) A randomised study comparing standard dose carboplatin with chlorambucil and carboplatin in advanced ovarian cancer. Br J Cancer 65:275–281

    Google Scholar 

  26. Rowinsky EK, Flood WA, Sartorius SE, Bowling KM, Ettinger DS (1997) Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. Invest New Drugs 15:129–138

    Article  CAS  PubMed  Google Scholar 

  27. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I (1997) Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer. Br J Cancer 75:301–305

    Google Scholar 

  28. Seymour L, Eisenhauer E (2001) A review of dose-limiting events in phase I trials: antimetabolites show unpredictable relationships between dose and toxicity. Cancer Chemother Pharmacol 47:2–10

    Article  CAS  PubMed  Google Scholar 

  29. Simon R, Freidlin B, Rubinstein L, Arbuck S, Collins J, Christian M (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147

    Article  CAS  PubMed  Google Scholar 

  30. ten Bokkel Huinink W, Veenhof C, Huizing M, Rodenhuis S, Helmerhorst T, Dubbelman R, Dalesio O, Beijnen J, Winograd B (1997) Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study. Semin Oncol 24 [Suppl 2]:31–33

  31. van Warmerdam LJ, Huizing MT, Giaccone G, Postmus PE, ten Bokkel Huinink WW, van Zandwijk N, Koolen MG, Helmerhorst TJ, van der Vijgh WJ, Veenhof CH, Beijnen JH (1997) Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 24 [Suppl 2]:97–104

  32. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, Moore A, Ellerton JA, Norton L, Ferree CR, Ballow A, Frei E, Henderson I (1994) Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253–1259

    Google Scholar 

  33. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH (2001) Estimation of glomerular filtration rate in cancer patients. Br J Cancer 84:452–459

    Google Scholar 

  34. Zujewski J, Horak ID, Bol CJ, Woestenborghs R, Bowden C, End DW, Piotrovsky VK, Chiao J, Belly RT, Todd A, Kopp WC, Kohler DR, Chow C, Noone M, Hakim FT, Larkin G, Gress RE, Nussenblatt RB, Kremer AB, Cowan KH (2000) Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 18:927–941

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research UK Trials Unit, University of Birmingham, Birmingham, B15 2TT, UK

    Sarah D. Jordan, Christopher J. Poole, Neil M. Steven & Andrea Burton

  2. University Hospital Birmingham NHS Trust, Birmingham, B15 2TH, UK

    Venice R. Archer

  3. St Chads Unit, City Hospital, Dudley Road, Birmingham, B18 7QH, UK

    Sarah D. Jordan

Authors
  1. Sarah D. Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christopher J. Poole
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Venice R. Archer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Neil M. Steven
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Andrea Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jordan, S.D., Poole, C.J., Archer, V.R. et al. A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens. Cancer Chemother Pharmacol 52, 113–118 (2003). https://doi.org/10.1007/s00280-003-0634-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0634-8

Keywords

Search

Navigation